NCI Definition: An aggressive malignant mixed epithelial and mesenchymal neoplasm that arises from the cervix and is characterized by the presence of malignant epithelial elements and malignant mesenchymal elements. 
There is 1 clinical trial for cervical carcinosarcoma, of which 1 is open and 0 are completed or closed. Of the trial that contains cervical carcinosarcoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
ERBB2 is the most frequent gene inclusion criterion for cervical carcinosarcoma clinical trials .
Paclitaxel and rebastinib tosylate are the most common interventions in cervical carcinosarcoma clinical trials.
Significant Genes in Cervical Carcinosarcoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and cervical carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.